Colchicine in Patients Undergoing Coronary Artery Bypass Grafting After Acute Coronary Syndrome
Status:
Recruiting
Trial end date:
2025-02-05
Target enrollment:
Participant gender:
Summary
The present study seeks to evaluate the effectiveness of the use of perioperative colchicine
with regard to operative complications, in patients with acute coronary syndrome and
indication for cardiac post-surgical revascularization.
Patients will be selected and randomized while still in the emergency room and medication
(colchicine 0.5mg every 12 hours or placebo) will be started within 24 hours of
randomization, being maintained for 30 days after surgery.